Anal dysplasia

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

Retrieved on: 
Tuesday, April 27, 2021
Medicine, Oncology, Histopathology, Medical research, Medical specialties, Health sciences, Inovio Pharmaceuticals, Precancerous condition, Anal dysplasia, Dysplasia, Carcinoma in situ, INO-4800

b'PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ --INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021.

Key Points: 
  • b'PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ --INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021.
  • Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m.
  • VGX-3100 also demonstrated positive Phase 2 efficacy results in separate trials evaluating the treatment of precancerousvulvar dysplasia and anal dysplasia.
  • INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors.

INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia

Retrieved on: 
Wednesday, February 24, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Health, Medicine, Medical software, Qiagen, Human papillomavirus infection, Cervical intraepithelial neoplasia, Inovio Pharmaceuticals, Anal dysplasia, HspE7

QIAGEN is contributing an extensive track record of developing and commercializing novel diagnostic tests," said Dr. J. Joseph Kim, INOVIO'sPresident andCEO.

Key Points: 
  • QIAGEN is contributing an extensive track record of developing and commercializing novel diagnostic tests," said Dr. J. Joseph Kim, INOVIO'sPresident andCEO.
  • QIAGEN and INOVIO in 2019 announced a collaboration to develop a companion diagnostic to guide clinical decision-making for the use of INOVIO's DNA-based immunotherapy to treat cervical dysplasia caused by HPV.
  • "We are pleased to support INOVIO by developing companion diagnostics to identify patients who would benefit from VGX-3100.
  • VGX-3100is INOVIO's DNA medicine in clinical trials for the treatment of three HPV-16/18 related disease states anal dysplasia, vulvar dysplasia, and cervical dysplasia.

INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia

Retrieved on: 
Thursday, March 26, 2020
Cancer, Medicine, Health, Infectious causes of cancer, Papillomavirus, RTT, Medical terminology, Anal dysplasia, Colorectal surgery, Precancerous condition, Human papillomavirus infection, Vulva

Anal dysplasia or anal HSIL, is an orphan disease that affects men and women in both immunocompetent and immunocompromised populations.

Key Points: 
  • Anal dysplasia or anal HSIL, is an orphan disease that affects men and women in both immunocompetent and immunocompromised populations.
  • Currently, the treatments for anal dysplasia are surgical excision, electro-cautery or laser therapy.
  • This open-label, multi-center Phase 2 study is designed to evaluate the safety and efficacy of VGX-3100 in adultswith precancerous anal dysplasia caused by HPV-16 and/or HPV-18.
  • INOVIO is in open-label Phase 2 clinical trials evaluating its efficacy for treating HPV-related vulvar and anal dysplasia (HSIL).

Orion Biotechnology's Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago

Retrieved on: 
Thursday, May 30, 2019
Cancer, Infectious causes of cancer, Papillomavirus, Gastrointestinal cancer, Anal cancer, RTT, Oncology, Intraepithelial neoplasia, Anal dysplasia, Human papillomavirus infection, Dysplasia, Anal Pap smear

His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.

Key Points: 
  • His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.
  • In the MTN-017 study which was conducted in the US, Peru, Thailand, and South Africa.
  • Dr. McGowan's laboratory showed that approximately 93% of MSM had evidence of anal HPV infection which is linked to the development of anal dysplasia and anal cancer (Cranston et al.
  • These patients should undergo regular surveillance to recognize and treat anal dysplasia to avoid progression to anal cancer," said Dr. McGowan.

Orion Biotechnology's Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago

Retrieved on: 
Thursday, May 30, 2019
Cancer, Infectious causes of cancer, Papillomavirus, Gastrointestinal cancer, Anal cancer, RTT, Oncology, Intraepithelial neoplasia, Anal dysplasia, Human papillomavirus infection, Dysplasia, Anal Pap smear

His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.

Key Points: 
  • His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.
  • In the MTN-017 study which was conducted in the US, Peru, Thailand, and South Africa.
  • Dr. McGowan's laboratory showed that approximately 93% of MSM had evidence of anal HPV infection which is linked to the development of anal dysplasia and anal cancer (Cranston et al.
  • These patients should undergo regular surveillance to recognize and treat anal dysplasia to avoid progression to anal cancer," said Dr. McGowan.